What is tesamorelin?
Tesamorelin is a synthetic, stabilised analogue of human growth hormone-releasing hormone (GHRH). Unlike exogenous recombinant human GH, it acts upstream — stimulating the anterior pituitary to secrete endogenous GH in a pulsatile, physiological pattern. This upstream mechanism differentiates it pharmacologically from direct GH administration and is central to its research profile.
The compound has been extensively studied in Phase 3 randomised controlled trials in HIV-infected adults with lipodystrophy-associated visceral adiposity. It carries the most robust clinical dataset of any GHRH analogue currently available as a research compound, making it a useful reference point when studying the GH-secretagogue class more broadly.
Molecular structure and stability
Native human GHRH (also called growth hormone-releasing factor, or GRF) is a 44-amino acid peptide produced in the hypothalamus. It is rapidly degraded in plasma by dipeptidyl peptidase IV (DPP-IV) and other proteases, with a plasma half-life of only a few minutes — making it impractical for study outside continuous infusion protocols.
Tesamorelin addresses this by incorporating a trans-3-hexenoic acid (E-hex) modification at the N-terminus of the native GHRH(1-44) sequence. This lipophilic modification:
- Protects the peptide from N-terminal DPP-IV cleavage
- Extends plasma half-life to approximately 20–30 minutes (vs. <2 minutes for native GHRH)
- Preserves full agonist activity at the GHRH receptor (GHRHR1)
- Maintains the full 44-amino-acid sequence that characterises native GHRH
Molecular weight: approximately 5,135 Da. CAS registry: 218949-48-5. The compound is water-soluble and is typically supplied as a lyophilised powder for reconstitution.
Mechanism: the GHRH–GH–IGF-1 axis

Tesamorelin binds selectively to the GHRH receptor (GHRHR1), a G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Receptor activation triggers:
- cAMP elevation — GHRHR1 is Gαs-coupled; activation raises intracellular cAMP via adenylyl cyclase
- PKA activation — elevated cAMP activates protein kinase A, which phosphorylates transcription factors driving GH gene expression
- Calcium influx — PKA-mediated phosphorylation of voltage-gated calcium channels increases cytosolic Ca²⁺, triggering exocytosis of GH-containing secretory granules
- GH pulse — the somatotroph releases a GH pulse into portal circulation, maintaining the ultradian pulsatile pattern characteristic of endogenous GH secretion
The liberated GH then acts on peripheral tissues. In the liver, GH binding to GHR stimulates the JAK2-STAT5 pathway, driving transcription of insulin-like growth factor 1 (IGF-1). Circulating IGF-1 is the primary mediator of GH's anabolic and lipolytic effects in peripheral tissues including adipose, muscle, and bone.
The key research distinction: because tesamorelin acts through the endogenous pituitary GH-releasing pathway, GH secretion remains subject to physiological negative feedback via somatostatin and IGF-1. This means GH levels cannot become supraphysiological in the way possible with exogenous GH — a pharmacological constraint with implications for the side-effect profile.
Tesamorelin vs. other GHRH analogues
| Compound | Length | Key modification | Approx. t½ | Phase 3 data? |
|---|---|---|---|---|
| Tesamorelin | 44 aa | N-terminal trans-hexenoic acid | ~25 min | Yes (HIV lipodystrophy) |
| Sermorelin | 29 aa | Truncated GHRH(1-29) | ~10 min | Limited (paediatric GHD) |
| CJC-1295 (DAC) | 29 aa | C8 fatty acid + maleimide (albumin binding) | Days | No |
| CJC-1295 (no DAC) | 29 aa | Amide C-terminus modification | ~30 min | No |
| Native GHRH(1-44) | 44 aa | None | <2 min | Infusion studies only |
The comparison table illustrates why tesamorelin occupies a unique position among GHRH research compounds: it combines the full-length native GHRH sequence (maximising receptor activity) with a clinically validated half-life extension strategy, and is supported by the largest randomised trial dataset of the class.
Phase 3 clinical trial data
Trial design
Two Phase 3 randomised, double-blind, placebo-controlled trials enrolled HIV-infected adults with antiretroviral therapy-associated central adiposity. Participants were randomised 2:1 to receive tesamorelin 2 mg subcutaneously daily or matching placebo for 26 weeks. A subset continued into a 26-week extension phase. Visceral adipose tissue (VAT) was the primary endpoint, measured by CT at the L4–L5 level.
Visceral adipose tissue reduction
Falutz et al. (AIDS 2008, PMID: 18690162) reported the long-term safety and efficacy data across both the initial 26-week and 52-week extension phases. Key findings:
- VAT decreased by approximately 18% from baseline at 52 weeks in the continuously treated group (p < 0.001 vs. baseline)
- Upon treatment discontinuation, VAT reaccumulated — emphasising that effects are treatment-dependent
- Triglycerides decreased by approximately 51 mg/dL at 52 weeks in the treatment group
- Glucose parameters showed no clinically significant worsening over 52 weeks
Metabolic correlates of VAT reduction
Stanley et al. (Clin Infect Dis 2012, PMID: 22495074) conducted a prespecified analysis examining whether VAT reduction mediated metabolic improvements. In subjects with ≥8% VAT reduction (defined as "responders"), compared with non-responders:
- Greater reduction in triglycerides at 26 and 52 weeks
- Attenuated increase in fasting glucose and HbA1c over 52 weeks
- Improvement in adiponectin levels
Importantly, metabolic improvements were correlated with VAT change rather than with IGF-1 elevation per se — a distinction relevant to understanding whether effects are downstream of VAT reduction or a direct action of GH/IGF-1 on metabolic pathways.
Response predictors and fat quality
Mangili et al. (PLoS One 2015, PMID: 26457580) analysed pooled Phase 3 data (n=806) to identify predictors of VAT response. Subjects with baseline metabolic syndrome (NCEP criteria), elevated triglycerides, or white race were more likely to achieve VAT reduction below 140 cm² (a threshold associated with lower cardiovascular risk). Odds of reaching this threshold were 3.9× greater for tesamorelin-treated subjects than placebo (95% CI 2.03–7.44).
Lake et al. (AIDS 2021, PMID: 33756511) extended analysis of the same cohorts to examine fat quality (CT density in Hounsfield units, a surrogate for adipocyte size). In VAT responders, both VAT and subcutaneous fat density increased significantly — independent of changes in fat quantity — suggesting effects on adipose tissue composition beyond simple volume reduction.
Liver fat and hepatic research
A separate randomised trial by Stanley et al. (JAMA 2014, PMID: 25038357) enrolled 50 HIV-infected adults with abdominal fat accumulation and measured liver fat by ¹H magnetic resonance spectroscopy (1H-MRS) — the gold-standard non-invasive hepatic fat quantification method. Tesamorelin 2 mg/day for 6 months produced a statistically significant reduction in liver fat fraction compared to placebo. This was among the first controlled data documenting liver fat reduction from a GHRH analogue in any population.
Fourman et al. (JCI Insight 2020, PMID: 32701508) subsequently leveraged paired liver biopsy specimens from the same trial to perform gene set enrichment analysis. Tesamorelin treatment:
- Upregulated hepatic gene sets for oxidative phosphorylation
- Downregulated gene sets contributing to inflammation, tissue repair, and cell division
- Reciprocally modulated gene sets associated with favourable vs. poor hepatocellular carcinoma prognosis
These findings are mechanistically noteworthy because they suggest tesamorelin may affect liver biology through GH-driven transcriptional reprogramming beyond simple fat reduction. They remain limited to HIV-positive research participants with NAFLD, and the clinical significance in general populations is unknown.
GHRH axis and cognitive research
The GHRH–GH–IGF-1 axis has independent effects on brain function. IGF-1 receptors are expressed throughout the central nervous system, particularly in hippocampus and prefrontal cortex. GH and IGF-1 levels decline with advancing age (somatopause), and this decline has been linked to aspects of cognitive ageing.
Ellis et al. (J Infect Dis 2025, PMID: 39813152) conducted a 6-month Phase 2 randomised open-label trial comparing tesamorelin 2 mg/day SC versus standard of care in 73 virally suppressed HIV-positive adults with abdominal obesity and neurocognitive impairment. Key findings:
- The tesamorelin group showed a trend toward improved neurocognitive performance at 6 months (mean change +0.146; 95% CI −0.002 to +0.294; p = 0.060)
- The standard-of-care group did not show improvement (mean change +0.103; p = 0.295)
- The between-group difference was not statistically significant (p = 0.673)
- IGF-1 levels increased in the tesamorelin group; changes did not correlate with neurocognitive improvement
- Waist circumference reduction was significantly greater in the tesamorelin group (median −2.7 cm; p = 0.015)
The study was limited by insufficient statistical power and absence of a placebo arm. No significant between-group difference in neurocognitive outcomes was detected. This remains an exploratory area requiring adequately powered placebo-controlled trials.
Pharmacokinetics and dosing context
Subcutaneous injection is the route used in all major tesamorelin trials. Key pharmacokinetic parameters observed in research settings:
- Absorption: rapid subcutaneous absorption, Tmax approximately 0.5–1 hour post-injection
- Distribution: primarily in plasma; low volume of distribution consistent with a peptide
- Metabolism: proteolytic degradation; the trans-hexenoic acid modification reduces but does not eliminate DPP-IV cleavage
- Elimination: plasma half-life approximately 20–30 minutes (compared to <2 minutes for native GHRH)
- IGF-1 response: peak IGF-1 elevation typically observed 12–24 hours after a daily injection; IGF-1 increases of 40–120% have been reported in clinical trials at 2 mg/day
In the Phase 3 trials, the dose of 2 mg/day subcutaneous was the studied dose for visceral adiposity. The cognitive function trial used 1 mg/day. No dose-response optimisation data in healthy adults is available from the clinical literature.
Reconstitution for research
Research-grade tesamorelin is supplied as a lyophilised powder in sterile vials. Standard reconstitution guidance for research settings:
- Storage: lyophilised powder at −20°C or per manufacturer specification. Protect from light.
- Reconstitution solvent: sterile water for injection (WFI). Do not use bacteriostatic water containing benzyl alcohol unless the specific product documentation specifies it.
- Technique: inject solvent against the vial wall; swirl gently. Do not shake — shaking accelerates peptide degradation.
- Concentration: typical research concentrations are 1–2 mg/mL. Higher concentrations may reduce solubility stability.
- Post-reconstitution storage: 2–8°C, use within 24–48 hours or per CoA documentation. Do not refreeze reconstituted solution.
- Sterile filtration: for in vivo research, filter through a 0.22 µm membrane under laminar flow.
For purity and identity verification, a Certificate of Analysis (CoA) should confirm ≥98% purity by HPLC, correct molecular weight by mass spectrometry, and endotoxin levels ≤1 EU/mg (LAL assay) for in vivo applications.
Research-grade tesamorelin at UNIK LAB
UNIK LAB supplies tesamorelin as a research compound with third-party CoA documentation (HPLC purity ≥98%, mass spec, endotoxin testing).
View Tesamorelin 5mg at UNIK LAB →Research limitations
Population-specific data
The majority of controlled tesamorelin clinical data derives from HIV-infected adults on antiretroviral therapy. This population has unique endocrine characteristics — including relative GH deficiency driven by visceral adiposity and antiretroviral metabolic effects — that are not representative of the general population. Extrapolation of efficacy or safety data to non-HIV subjects is not supported by controlled evidence.
Effect durability
Both VAT reduction and the cognitive effects observed in trials did not persist after treatment discontinuation. This suggests that tesamorelin's effects are pharmacologically maintained rather than disease-modifying. From a research standpoint, this characteristic allows for washout designs but limits the interpretation of any off-treatment data.
IGF-1 and glucose effects
Tesamorelin increases IGF-1, which in turn has complex effects on insulin signalling. The Phase 3 trials showed no clinically significant worsening of glucose parameters at the 2 mg/day dose over 52 weeks. However, research subjects with pre-existing insulin resistance or type 2 diabetes require careful monitoring — and this population was explicitly managed in the trial protocols.
Regulatory status
Tesamorelin products supplied by UNIK LAB are research compounds and are not approved for human therapeutic use. No claims of therapeutic efficacy are made. Researchers must comply with applicable institutional and regulatory requirements governing research peptide use in their jurisdiction.
Frequently Asked Questions
What is tesamorelin?
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) consisting of the native 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoic acid modification that extends its plasma half-life. It acts on the pituitary GHRH receptor (GHRHR1) to stimulate endogenous, pulsatile growth hormone secretion rather than delivering exogenous GH. It has been studied in Phase 3 randomised controlled trials for HIV-associated visceral adiposity.
How does tesamorelin differ from CJC-1295 or sermorelin?
All three are GHRH analogues but differ in structure and half-life. Sermorelin is a truncated 29-amino-acid GHRH fragment. CJC-1295 with DAC binds albumin for a half-life of days; without DAC it lasts approximately 30 minutes. Tesamorelin is the full-length 44-amino-acid GHRH with an N-terminal lipid modification, giving it ~25 minutes half-life. Tesamorelin has the most extensive Phase 3 clinical trial dataset of the three.
What did the Phase 3 trials show about tesamorelin?
Two randomised, double-blind, placebo-controlled trials in HIV-infected adults with abdominal fat accumulation found that tesamorelin 2 mg/day subcutaneously for 26–52 weeks reduced visceral adipose tissue by approximately 15–18% vs. placebo (Falutz et al., AIDS 2008, PMID: 18690162). Triglycerides decreased and metabolic parameters improved in VAT responders (Stanley et al., Clin Infect Dis 2012, PMID: 22495074). Effects reversed upon treatment discontinuation.
Does tesamorelin stimulate natural GH or deliver exogenous GH?
Tesamorelin stimulates the anterior pituitary to release endogenous GH — it does not supply exogenous GH. This is the core pharmacological distinction of all GHRH analogues vs. recombinant human GH (rhGH). Because GH release remains subject to physiological negative feedback via somatostatin and IGF-1, GH levels cannot reach the supraphysiological levels associated with direct rhGH administration.
What quality standards apply to research-grade tesamorelin?
Research-grade tesamorelin should have: ≥98% purity by HPLC, mass spectrometry confirmation of molecular weight (~5,135 Da), endotoxin ≤1 EU/mg by LAL assay for in vivo studies, and a valid CoA from a third-party analytical laboratory. UNIK LAB provides full CoA documentation with each batch.
Is tesamorelin available at UNIK LAB?
Yes. UNIK LAB supplies tesamorelin 5mg as a research compound with full third-party CoA documentation. It is available for research purposes only and is not intended for human therapeutic use.
